Research programme: CDKL5 program- Amicus Therapeutics/ MiaMed

Drug Profile

Research programme: CDKL5 program- Amicus Therapeutics/ MiaMed

Alternative Names: CDKL5

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MiaMED
  • Developer Amicus Therapeutics
  • Class
  • Mechanism of Action Cyclin-dependent kinase 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders

Most Recent Events

  • 12 Jul 2016 Preclinical trials in Neurological disorders in USA (unspecified route)
  • 06 Jul 2016 MiaMED has been acquired by Amicus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top